[1] 高岩.天疱疮患者血清抗桥粒芯糖蛋白抗体与疾病临床特征的相关性研究[J]. 现代医学,2014,42(6):648-651.
[2] 周亚男,黄丹,郝秋巧,等.天疱疮患者长期服用糖皮质激素对骨密度的影响[J]. 现代医学,2019,47(12):1498-1500.
[3] 周琛,宁学玲,陈勇,等.重症寻常型天疱疮60例临床分析[J]. 广东医科大学学报,2018,36(4):428-430.
[4] 楼小航,刘继峰,吴纪龙,等.大疱性类天疱疮患者感染分析[J]. 中华医院感染学杂志,2017,27(9):2009-2011,2019.
[5] 李湘燕,吕媛.低蛋白血症对危重症患者抗菌药物疗效的影响[J]. 中华结核和呼吸杂志,2018,41(8):600-603.
[6] BAI Y X,ZHANG L M,XIAO T,et al.A 6-year treatment experience for pemphigus:retrospective study of 69 Chinese patients[J]. Dermatol Ther,2016,29:84-87.
[7] 赵孝琴,鲍光明.大疱性类天疱疮52例临床分析[J]. 中国麻风皮肤病杂志,2007(5):451-452.
[8] RASHID H,LAMBERTS A,MAANEN D A,et al.The effectiveness of rituximab in pemphigus,and the benefit of additional maintenance infusions:daily practice data from a retrospective study[J]. J Am Acad Dermatol,2020,83:1503-1505.
[9] SHIMANOVICH I,BAUMANN T,SCHMIDT E,et al.Long-term outcomes of rituximab therapy in pemphigus[J]. J Eur Acad Dermatol Venereol,2020,34:2884-2889.
[10] PAWAR M.Topical insulin in the treatment of nonhealing erosions and ulcers of pemphigus vulgaris[J]. J Am Acad Dermatol,2020,S0190-9622(20)31065-3. |